News

Targeted Oncology11d
FDA Actions in Oncology: April 2025 Approvals and Designations
A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...
FDA grants accelerated approval to avutometinib, defactinib combination
On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...
A new era in cancer therapies is at hand
The cells targeted the cancer and eradicated it. Thirteen years later, Whitehead is still cancer-free. Since then, however, ...
The American Journal of Managed Care4d
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...
PharmExec4d
FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...
PMLive1d
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...